index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
8501,Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis,"Augmentation cystoplasty is the mainstay of surgical treatment for medically refractory neurogenic bladder in patients with spina bifida. Concerns regarding an increased risk of malignancy have prompted many centers to consider routine postoperative screening. We examine the potential cost-effectiveness of such screening.A Markov model was used to compare 2 screening strategies among patients with spina bifida after cystoplasty, namely annual screening cystoscopy and cytology and usual care. Model parameters were informed via a systematic review of post-augmentation malignancy and cost estimates from published reports or government sources.In a hypothetical cohort the individual increase in life expectancy for the entire cohort was 2.3 months with an average lifetime cost of $55,200 per capita, for an incremental cost-effectiveness ratio of $273,718 per life-year gained. One-way and two-way sensitivity analyses suggest the screening strategy could be cost effective if the annual rate of cancer development were more than 0.26% (12.8% lifetime risk) or there were a greater than 50% increase in screening effectiveness and cancer risk after augmentation. After adjusting for multiple levels of uncertainty the screening strategy had only an 11% chance of being cost effective at a $100,000 per life-year threshold or a less than 3% chance of being cost effective at $100,000 per quality adjusted life-year.Annual screening for malignancy among patients with spina bifida with cystoplasty using cystoscopy and cytology is unlikely to be cost effective at commonly accepted willingness to pay thresholds. This conclusion is sensitive to a higher than expected risk of malignancy and to highly optimistic estimates of screening effectiveness.",2011-01-08068,21855939,J Urol,Paul J Kokorowski,2011,186 /,1437-43,No,21855939,"Paul J Kokorowski; Jonathan C Routh; Joseph G Borer; Carlos R Estrada; Stuart B Bauer; Caleb P Nelson; Screening for malignancy after augmentation cystoplasty in children with spina bifida: a decision analysis, J Urol, ; 186 ():0022-5347; 1437-43",QALY,Not Stated,Not Stated,Not Stated,Annual screening for malignancy using cystoscopy and cytology and usual care vs. Usual care (annual office visit and renal ultrasound),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,Not Stated,United States,2010,Not Stated
8502,Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis,"A probabilistic model was developed to determine the cost-effectiveness of three biologics, etanercept, infliximab and adalimumab, compared with palliative care for the treatment of active and progressive PsA in patients who have an inadequate response to standard treatment (including DMARDs).A previous model was revised to evaluate the impact of biologics on both skin and joint disease and to include new evidence from the clinical review and evidence synthesis. Initial response to biologics was determined using the PsA response criteria. The impact of biologics on the arthritis component of the disease is then modelled via a change in the HAQ and the impact of the psoriasis component measured using the Psoriasis Area and Severity Index.For PsA patients with mild to moderate skin disease, the incremental cost-effectiveness ratio (ICER) for etanercept vs palliative care is around ?18 000, and the ICER for infliximab vs etanercept is around ?44 000 per quality-adjusted life year (QALY). Adalimumab is extendedly dominated. The probability that etanercept is cost effective is 0.436 at a threshold of ?20 000 per QALY. Etanercept is also likely to be cost effective for patients with moderate to severe psoriasis or negligible skin involvement.Further investigation is required to reduce uncertainties around a number of model parameters, in particular the length of time over which biologics are assumed to be effective and the progression of HAQ on and off treatment.",2011-01-08070,21859705,Rheumatology (Oxford),Laura Bojke,2011,50 Suppl 4 /,iv39-iv47,No,21859705,"Laura Bojke; David Epstein; Dawn Craig; Mark Rodgers; Nerys Woolacott; Huiqin Yang; Mark Sculpher; Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis, Rheumatology (Oxford), ; 50 Suppl 4 ():1462-0324; iv39-iv47",QALY,Not Stated,Not Stated,Not Stated,Etanercept vs. Palliative care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,40 Years,3.50,3.50,15986,United Kingdom,2008,35636.47
8503,Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis,"A probabilistic model was developed to determine the cost-effectiveness of three biologics, etanercept, infliximab and adalimumab, compared with palliative care for the treatment of active and progressive PsA in patients who have an inadequate response to standard treatment (including DMARDs).A previous model was revised to evaluate the impact of biologics on both skin and joint disease and to include new evidence from the clinical review and evidence synthesis. Initial response to biologics was determined using the PsA response criteria. The impact of biologics on the arthritis component of the disease is then modelled via a change in the HAQ and the impact of the psoriasis component measured using the Psoriasis Area and Severity Index.For PsA patients with mild to moderate skin disease, the incremental cost-effectiveness ratio (ICER) for etanercept vs palliative care is around ?18 000, and the ICER for infliximab vs etanercept is around ?44 000 per quality-adjusted life year (QALY). Adalimumab is extendedly dominated. The probability that etanercept is cost effective is 0.436 at a threshold of ?20 000 per QALY. Etanercept is also likely to be cost effective for patients with moderate to severe psoriasis or negligible skin involvement.Further investigation is required to reduce uncertainties around a number of model parameters, in particular the length of time over which biologics are assumed to be effective and the progression of HAQ on and off treatment.",2011-01-08070,21859705,Rheumatology (Oxford),Laura Bojke,2011,50 Suppl 4 /,iv39-iv47,No,21859705,"Laura Bojke; David Epstein; Dawn Craig; Mark Rodgers; Nerys Woolacott; Huiqin Yang; Mark Sculpher; Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis, Rheumatology (Oxford), ; 50 Suppl 4 ():1462-0324; iv39-iv47",QALY,Not Stated,Not Stated,Not Stated,Infliximab vs. Etanercept,Not Stated,Not Stated,Not Stated,"Female, Male",Full,40 Years,3.50,3.50,53742.86,United Kingdom,2008,119805.19
8504,Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis,"A probabilistic model was developed to determine the cost-effectiveness of three biologics, etanercept, infliximab and adalimumab, compared with palliative care for the treatment of active and progressive PsA in patients who have an inadequate response to standard treatment (including DMARDs).A previous model was revised to evaluate the impact of biologics on both skin and joint disease and to include new evidence from the clinical review and evidence synthesis. Initial response to biologics was determined using the PsA response criteria. The impact of biologics on the arthritis component of the disease is then modelled via a change in the HAQ and the impact of the psoriasis component measured using the Psoriasis Area and Severity Index.For PsA patients with mild to moderate skin disease, the incremental cost-effectiveness ratio (ICER) for etanercept vs palliative care is around ?18 000, and the ICER for infliximab vs etanercept is around ?44 000 per quality-adjusted life year (QALY). Adalimumab is extendedly dominated. The probability that etanercept is cost effective is 0.436 at a threshold of ?20 000 per QALY. Etanercept is also likely to be cost effective for patients with moderate to severe psoriasis or negligible skin involvement.Further investigation is required to reduce uncertainties around a number of model parameters, in particular the length of time over which biologics are assumed to be effective and the progression of HAQ on and off treatment.",2011-01-08070,21859705,Rheumatology (Oxford),Laura Bojke,2011,50 Suppl 4 /,iv39-iv47,No,21859705,"Laura Bojke; David Epstein; Dawn Craig; Mark Rodgers; Nerys Woolacott; Huiqin Yang; Mark Sculpher; Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis, Rheumatology (Oxford), ; 50 Suppl 4 ():1462-0324; iv39-iv47",QALY,Not Stated,Not Stated,Not Stated,Adalimumab vs. Palliative care,Not Stated,Not Stated,Not Stated,"Female, Male",Full,40 Years,3.50,3.50,17275.52,United Kingdom,2008,38511.1
8505,Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial,"The REDUCE trial examined whether chemoprevention with the dual 5-alpha reductase inhibitor, dutasteride, reduced risk of prostate cancer (PCa) detection on biopsy.We examined the cost effectiveness of dutasteride compared with placebo in preventing PCa in men at increased risk as seen in REDUCE, from a US payer perspective.A Markov model was developed to compare costs and outcomes of chemoprevention with dutasteride 0.5?mg/day or placebo with usual care in men aged 50-75 years, with serum prostate-specific antigen (PSA) of 2.5-10?ng/mL (men aged <60 years) or 3.0-10?ng/mL (men aged =60 years), and with a single negative prostate biopsy in the prior 6 months. The model simulated the REDUCE cohort annually through different health states over 4-, 10-year and lifetime time horizons. Risks of PCa for men receiving placebo and dutasteride were obtained from REDUCE. Rates of acute urinary retention events and benign prostate hyperplasia-related surgeries also came from REDUCE. Costs and utilities were obtained from published literature. All costs are reported in $US, year 2009 values. Results: The model indicated that, over 10 years, dutasteride patients would experience fewer PCas (251 vs 312 per 1000 patients) at increased cost ($US15?341 vs $US12?316) than placebo patients. Although life-years were not substantially affected, the model calculated an increase in QALYs of 0.14 for dutasteride patients. Chemoprevention with dutasteride appeared to be cost effective, with an incremental cost per QALY of $US21?781 and cost per PCa avoided of $US50?254. The 4-year and lifetime incremental costs per QALY were $US18?409 and $US22?498, respectively.Despite increased cost due to taking a drug for prevention, dutasteride 0.5?mg/day may be cost effective in men at increased risk for PCa.",2011-01-08073,21875161,Appl Health Econ Health Policy,Michael W Kattan,2011,9 /,305-15,Yes,21875161,"Michael W Kattan; Stephanie R Earnshaw; Cheryl L McDade; Libby K Black; Gerald L Andriole; Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial, Appl Health Econ Health Policy, ; 9 ():1179-1896; 305-15",QALY,Not Stated,Not Stated,Not Stated,Usual care plus chemoprevention with dutasteride (0.5 mg/day) vs. Usual care plus placebo,Not Stated,75 Years,50 Years,Male,Full,Lifetime,Not Stated,Not Stated,21781,United States,2009,26275.94
8506,Cost-utility of bariatric surgery for morbid obesity in Finland,"The aim of this study was to evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve gastrectomy and gastric banding) compared with ordinary treatment in the Finnish healthcare system.Analysis was done from a healthcare provider's perspective using a combination of a decision tree and a Markov model, with a time horizon of 10 years. Health-related quality of life was estimated from a representative population survey, and other parameter values were based on registers, systematic reviews, controlled studies and expert opinion.In the base-case analysis, bariatric surgery was both more effective and less costly than the ordinary treatment. The mean costs were ?33,870 and ?50,495, and the mean number of quality-adjusted life-years 7?63 and 7?05, for bariatric surgery and ordinary treatment respectively. Uncertainty around the parameter values was tested comprehensively in sensitivity analyses, and the results were robust.Surgery for morbid obesity increases health-related quality of life, and reduces the need for further treatments and total healthcare costs. According to this analysis, non-operative care would be more costly for the Finnish healthcare system on average after 5 years following surgery.",2011-01-08077,21887777,J Clin Psychopharmacol,S M?klin,2011,98 /,1422-9,No,21887777,"S M?klin; A Malmivaara; M Linna; M Victorzon; V Koivukangas; H Sintonen; Cost-utility of bariatric surgery for morbid obesity in Finland, J Clin Psychopharmacol, ; 98 ():0271-0749; 1422-9",QALY,Not Stated,Not Stated,Not Stated,Bariatric surgery (all types) vs. Brief advice to intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-40301.73,Euro,2010,-63305.53
8507,Cost-utility of bariatric surgery for morbid obesity in Finland,"The aim of this study was to evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve gastrectomy and gastric banding) compared with ordinary treatment in the Finnish healthcare system.Analysis was done from a healthcare provider's perspective using a combination of a decision tree and a Markov model, with a time horizon of 10 years. Health-related quality of life was estimated from a representative population survey, and other parameter values were based on registers, systematic reviews, controlled studies and expert opinion.In the base-case analysis, bariatric surgery was both more effective and less costly than the ordinary treatment. The mean costs were ?33,870 and ?50,495, and the mean number of quality-adjusted life-years 7?63 and 7?05, for bariatric surgery and ordinary treatment respectively. Uncertainty around the parameter values was tested comprehensively in sensitivity analyses, and the results were robust.Surgery for morbid obesity increases health-related quality of life, and reduces the need for further treatments and total healthcare costs. According to this analysis, non-operative care would be more costly for the Finnish healthcare system on average after 5 years following surgery.",2011-01-08077,21887777,J Clin Psychopharmacol,S M?klin,2011,98 /,1422-9,No,21887777,"S M?klin; A Malmivaara; M Linna; M Victorzon; V Koivukangas; H Sintonen; Cost-utility of bariatric surgery for morbid obesity in Finland, J Clin Psychopharmacol, ; 98 ():0271-0749; 1422-9",QALY,Not Stated,Not Stated,Not Stated,Gastric bypass vs. Brief advice to intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-27441.27,Euro,2010,-43104.46
8508,Cost-utility of bariatric surgery for morbid obesity in Finland,"The aim of this study was to evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve gastrectomy and gastric banding) compared with ordinary treatment in the Finnish healthcare system.Analysis was done from a healthcare provider's perspective using a combination of a decision tree and a Markov model, with a time horizon of 10 years. Health-related quality of life was estimated from a representative population survey, and other parameter values were based on registers, systematic reviews, controlled studies and expert opinion.In the base-case analysis, bariatric surgery was both more effective and less costly than the ordinary treatment. The mean costs were ?33,870 and ?50,495, and the mean number of quality-adjusted life-years 7?63 and 7?05, for bariatric surgery and ordinary treatment respectively. Uncertainty around the parameter values was tested comprehensively in sensitivity analyses, and the results were robust.Surgery for morbid obesity increases health-related quality of life, and reduces the need for further treatments and total healthcare costs. According to this analysis, non-operative care would be more costly for the Finnish healthcare system on average after 5 years following surgery.",2011-01-08077,21887777,J Clin Psychopharmacol,S M?klin,2011,98 /,1422-9,No,21887777,"S M?klin; A Malmivaara; M Linna; M Victorzon; V Koivukangas; H Sintonen; Cost-utility of bariatric surgery for morbid obesity in Finland, J Clin Psychopharmacol, ; 98 ():0271-0749; 1422-9",QALY,Not Stated,Not Stated,Not Stated,Sleeve gastrectomy vs. Brief advice to intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-29684.91,Euro,2010,-46628.74
8509,Cost-utility of bariatric surgery for morbid obesity in Finland,"The aim of this study was to evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve gastrectomy and gastric banding) compared with ordinary treatment in the Finnish healthcare system.Analysis was done from a healthcare provider's perspective using a combination of a decision tree and a Markov model, with a time horizon of 10 years. Health-related quality of life was estimated from a representative population survey, and other parameter values were based on registers, systematic reviews, controlled studies and expert opinion.In the base-case analysis, bariatric surgery was both more effective and less costly than the ordinary treatment. The mean costs were ?33,870 and ?50,495, and the mean number of quality-adjusted life-years 7?63 and 7?05, for bariatric surgery and ordinary treatment respectively. Uncertainty around the parameter values was tested comprehensively in sensitivity analyses, and the results were robust.Surgery for morbid obesity increases health-related quality of life, and reduces the need for further treatments and total healthcare costs. According to this analysis, non-operative care would be more costly for the Finnish healthcare system on average after 5 years following surgery.",2011-01-08077,21887777,J Clin Psychopharmacol,S M?klin,2011,98 /,1422-9,No,21887777,"S M?klin; A Malmivaara; M Linna; M Victorzon; V Koivukangas; H Sintonen; Cost-utility of bariatric surgery for morbid obesity in Finland, J Clin Psychopharmacol, ; 98 ():0271-0749; 1422-9",QALY,Not Stated,Not Stated,Not Stated,Gastric banding vs. Brief advice to intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-37380,Euro,2010,-58716.11
8510,Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected],No abstract available,2011-01-08078,21887778,J Clin Psychopharmacol,M Adamina,2011,98 /,1430,No,21887778,"M Adamina; Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected], J Clin Psychopharmacol, ; 98 ():0271-0749; 1430",QALY,Not Stated,Not Stated,Not Stated,Gastric banding bariatric surgery vs. Ordinary treatment including brief advice from physicians and intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-37380,Euro,2010,-58716.11
8511,Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected],No abstract available,2011-01-08078,21887778,J Clin Psychopharmacol,M Adamina,2011,98 /,1430,No,21887778,"M Adamina; Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected], J Clin Psychopharmacol, ; 98 ():0271-0749; 1430",QALY,Not Stated,Not Stated,Not Stated,Gastric bypass bariatric surgery vs. Ordinary treatment including brief advice from physicians and intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-27441.27,Euro,2010,-43104.46
8512,Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected],No abstract available,2011-01-08078,21887778,J Clin Psychopharmacol,M Adamina,2011,98 /,1430,No,21887778,"M Adamina; Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected], J Clin Psychopharmacol, ; 98 ():0271-0749; 1430",QALY,Not Stated,Not Stated,Not Stated,Sleeve gastrectomy bariatric surgery vs. Ordinary treatment including brief advice from physicians and intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-29684.91,Euro,2010,-46628.74
8513,Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected],No abstract available,2011-01-08078,21887778,J Clin Psychopharmacol,M Adamina,2011,98 /,1430,No,21887778,"M Adamina; Cost-utility of bariatric surgery for morbid obesity in Finland (Br J Surg 2011; 98: 1422?1429) [corrected], J Clin Psychopharmacol, ; 98 ():0271-0749; 1430",QALY,Not Stated,Not Stated,Not Stated,All bariatric surgery procedures vs. Ordinary treatment including brief advice from physicians and intensive conservative treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,10 Years,3.00,3.00,-40301.73,Euro,2010,-63305.53
8514,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,50 Years,50 Years,Male,Full,Lifetime,3.00,3.00,149000,United States,2006,191283.92
8515,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,60 Years,60 Years,Male,Full,Lifetime,3.00,3.00,135000,United States,2006,173310.94
8516,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,70 Years,70 Years,Male,Full,Lifetime,3.00,3.00,169000,United States,2006,216959.62
8517,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,50 Years,50 Years,Female,Full,Lifetime,3.00,3.00,137000,United States,2006,175878.51
8518,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,126000,United States,2006,161756.88
8519,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,70 Years,70 Years,Female,Full,Lifetime,3.00,3.00,159000,United States,2006,204121.77
8520,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,70 Years,70 Years,Male,Full,Lifetime,3.00,3.00,166000,United States,2006,213108.26
8521,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,110000,United States,2006,141216.32
8522,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,70 Years,70 Years,Male,Full,Lifetime,3.00,3.00,147000,United States,2006,188716.35
8523,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,112000,United States,2006,143783.89
8524,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,70 Years,70 Years,Male,Full,Lifetime,3.00,3.00,149000,United States,2006,191283.92
8525,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer vs. None,Not Stated,60 Years,60 Years,Female,Full,Lifetime,3.00,3.00,112000,United States,2006,143783.89
8526,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer and bupropion and nicotine replacement therapy to current smokers at the screening examination vs. None,Not Stated,50 Years,50 Years,Male,Full,Lifetime,3.00,3.00,144500,United States,2006,185506.89
8527,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual computed tomography (CT) screening for lung cancer and bupropion and nicotine replacement therapy to current smokers at the screening examination vs. None,Not Stated,50 Years,50 Years,Female,Full,Lifetime,3.00,3.00,130500,United States,2006,167533.91
8528,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual smoking cessation therapy vs. None,Not Stated,50 Years,50 Years,Male,Full,Lifetime,3.00,3.00,57600,United States,2006,73946
8529,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,Annual smoking cessation therapy vs. None,Not Stated,50 Years,50 Years,Female,Full,Lifetime,3.00,3.00,69400,United States,2006,89094.66
8530,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,One-time smoking cessation therapy vs. None,Not Stated,50 Years,50 Years,Male,Full,Lifetime,3.00,3.00,49100,United States,2006,63033.83
8531,Cost-effectiveness of computed tomography screening for lung cancer in the United States,"A randomized trial has demonstrated that lung cancer screening reduces mortality. Identifying participant and program characteristics that influence the cost-effectiveness of screening will help translate trial results into benefits at the population level.Six U.S. cohorts (men and women aged 50, 60, or 70 years) were simulated in an existing patient-level lung cancer model. Smoking histories reflected observed U.S. patterns. We simulated lifetime histories of 500,000 identical individuals per cohort in each scenario. Costs per quality-adjusted life-year gained ($/QALY) were estimated for each program: computed tomography screening; stand-alone smoking cessation therapies (4-30% 1-year abstinence); and combined programs.Annual screening of current and former smokers aged 50 to 74 years costs between $126,000 and $169,000/QALY (minimum 20 pack-years of smoking) or $110,000 and $166,000/QALY (40 pack-year minimum), when compared with no screening and assuming background quit rates. Screening was beneficial but had a higher cost per QALY when the model included radiation-induced lung cancers. If screen participation doubled background quit rates, the cost of annual screening (at age 50 years, 20 pack-year minimum) was below $75,000/QALY. If screen participation halved background quit rates, benefits from screening were nearly erased. If screening had no effect on quit rates, annual screening costs more but provided fewer QALYs than annual cessation therapies. Annual combined screening/cessation therapy programs at age 50 years costs $130,500 to $159,700/QALY, when compared with annual stand-alone cessation.The cost-effectiveness of computed tomography screening will likely be strongly linked to achievable smoking cessation rates. Trials and further modeling should explore the consequences of relationships between smoking behaviors and screen participation.",2011-01-08082,21892105,J Thorac Oncol,Pamela M McMahon,2011,7 / 10,1841-8,No,21892105,"Pamela M McMahon; Chung Yin Kong; Colleen Bouzan; Milton C Weinstein; Lauren E Cipriano; Angela C Tramontano; Bruce E Johnson; Jane C Weeks; G Scott Gazelle; Cost-effectiveness of computed tomography screening for lung cancer in the United States, J Thorac Oncol, ; 7(10):1556-1380; 1841-8",QALY,Not Stated,Not Stated,Not Stated,One-time smoking cessation therapy vs. None,Not Stated,50 Years,50 Years,Female,Full,Lifetime,3.00,3.00,69300,United States,2006,88966.28
8532,Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib,"To estimate the cost-effectiveness (cost per additional life-year [LY] and quality-adjusted life-year [QALY] gained) of lenalidomide plus dexamethasone (LEN/DEX) compared with bortezomib for the treatment of relapsed-refractory multiple myeloma (rrMM) in Norway.A discrete-event simulation model was developed to predict patients? disease course using patient data, best response, and efficacy levels obtained from LEN/DEX MM-009/-010 trials and the bortezomib (APEX) published clinical trial. Predictive equations for time-to-progression (TTP) and post-progression survival (PPS) were developed by identifying the best fitting parametric survival distributions and selecting the most significant predictors. Disease and adverse event management was obtained via survey from Norwegian experts. Costs, derived from official Norwegian pricing data bases, included drug, administration, monitoring, and adverse event management costs.Complete or partial responders were 65% for LEN/DEX compared to 43% for bortezomib. Derived median TTP was 11.45 months for LEN/DEX compared to 5.15 months for bortezomib. LYs and QALYs were higher for LEN/DEX (4.06 and 2.95, respectively) than for bortezomib (3.11 and 2.19, respectively). The incremental costs per QALY and LY gained from LEN/DEX were NOK 247,978 and NOK 198,714, respectively, compared to bortezomib. Multiple sensitivity analyses indicated the findings were stable. The parameters with the greatest impact were 4-year time horizon (NOK 441,457/QALY) and higher bound confidence intervals for PPS (NOK 118,392).The model analyzed two therapies not compared in head-to-head trials, and predicted results using an equation incorporating patient-level characteristics. It is a limited estimation of the costs and outcomes in a Norwegian setting.The simulation model showed that treatment with LEN/DEX leads to greater LYs and QALYs when compared to bortezomib in the treatment of rrMM patients. The incremental cost-effectiveness ratio indicated treatment with LEN/DEX to be cost-effective and was the basis of the reimbursement approval of LEN/DEX in Norway.",2011-01-08083,21892856,J Med Econ,J?rgen M?ller,2011,14 /,690-7,Yes,21892856,"J?rgen M?ller; Lars Nicklasson; Ananthram Murthy; Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib, J Med Econ, ; 14 ():1369-6998; 690-7",QALY,Not Stated,Not Stated,Not Stated,Lenalidomide plus dexamethasone vs. Bortezomib,Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,4.00,4.00,247078,Norway,2010,48578.71
8533,Cost-effectiveness analysis of the bone-anchored hearing device,"To establish the cost-effectiveness of a bone-anchored hearing device (BAHD). To date, there has not been any formal economic analysis of this treatment.A prospective cohort case-control analysis.Tertiary referral center, university hospital.Between April 2007 and June 2008, all adult patients undergoing their first BAHD were contacted and invited to take part in this study. Data of 70 patients were completed during the study period and were analyzed.A health utility measure was made before and after the insertion of a BAHD to estimate the utility gain associated with this intervention.The cost and quality-adjusted life year (QALY) gain for each patient was established, and an incremental cost-effectiveness ratio (ICER) was calculated.The results of our analysis are that, compared with current standard care, the BAHD has an ICER of ?17,610 (US $26,415) per QALY gained. The National Institute for Health and Clinical Excellence will endorse a health intervention as cost-effective if the ICER is below ?20,000 to ?30,000 per QALY (US $30,000-45,000).This technology is likely to be cost-effective at the current thresholds used by National Institute for Health and Clinical Excellence. Therefore, this study suggests the BAHD may be a cost-effective method of auditory rehabilitation.",2011-01-08102,21909045,Otol Neurotol,Peter Monksfield,2011,32 /,1192-7,No,21909045,"Peter Monksfield; Sue Jowett; Andrew Reid; David Proops; Cost-effectiveness analysis of the bone-anchored hearing device, Otol Neurotol, ; 32 ():1531-7129; 1192-7",QALY,Not Stated,Not Stated,Not Stated,Bone-anchored hearing device (BAHD) vs. Standard care with distal aide,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,17610,United Kingdom,2008,39256.74
8534,Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up,"A multicenter, randomized, controlled, cost-effectiveness analysis.To assess the cost-effectiveness of balloon kyphoplasty (BKP) compared with standard medical treatment (control) in patients with acute/subacute (<3 months) vertebral compression fracture (VCF) due to osteoporosis.Patients with a VCF due to osteoporosis are common and will increase in number in an aging population, putting a substantial strain on health care. Selected patients may benefit from stabilizing the fracture with cement through BKP, a minimally invasive procedure. BKP has been reported to give good short-time clinical results, and economic modeling has suggested that the procedure could be cost-effective after 2 years compared with standard treatment.Hospitalized patients with back pain due to VCF were randomized to BKP or to control using a computer-generated random list. All costs associated with VCF and cost-effectiveness were reported primarily from the perspective of society. We used EQ-5D to assess quality of life (QoL). The accumulated quality-adjusted life years (QALYs) gained and costs/QALY gained were assessed using intention to treat.Between February 2003 and December 2005, a total of 63 out of 67 Swedish patients were analyzed: BKP (n = 32) and control (n = 31). Societal cost per patient for BKP was SEK 160,017 (SD = 151,083) = ?16,668 (SD = 15,735), and for control SEK 84,816 (SD = 40,954) = ?8835 (SD = 4266), a significant difference of 75,198 (95% confidence intervals [CI] = 16,037-120,104) = ?7833 (95% CI = 1671-12,511). The accumulated difference in QALYs was 0.085 (95% CI = -0.132 to 0.306) in favor of BKP. Cost/QALY gained using BKP was SEK 884,682 = ?92,154 and US $134,043.In this randomized controlled trial, it was not possible to demonstrate that BKP was cost-effective compared with standard medical treatment in patients treated for an acute/subacute vertebral fracture due to osteoporosis. However, sensitivity analysis indicated a certain degree of uncertainty, which needs to be considered.",2011-01-08109,21912321,Spine (Phila Pa 1976) Spine (Phila Pa 1976),Peter Fritzell,2011,36 /,2243-51,No,21912321,"Peter Fritzell; Acke Ohlin; Fredrik Borgstrm; Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up, Spine (Phila Pa 1976) Spine (Phila Pa 1976) , ; 36 ():1528-1159; 2243-51",QALY,Sweden,Not Stated,Not Stated,"Balloon kyphoplasty, vs. Standard medical treatment",Not Stated,Not Stated,Not Stated,"Female, Male",Full,24 Months,Not Stated,Not Stated,884682,Sweden,2008,163389.29
8535,Modelling correlated clinical outcomes in health technology appraisal,"Many clinical treatments have multiple effects that can only be effectively captured on multiple outcome scales. It might be important to understand how these outcomes are correlated to evaluate the effectiveness and cost-effectiveness of treatments in decision models.The probabilities are estimated that both, one, or neither outcome occurs, given estimates of the marginal probability for each outcome and information about the correlation between them. Methods are shown for different measures of association. Lower and upper bounds for the correlation coefficient are calculated for given values of the marginal probabilities. The approach is illustrated using a simplified decision model based on a recent evaluation of adalimumab, a biologic drug for psoriatic arthritis.Assuming the outcomes are positively correlated, the probability of both a skin and arthritis response after adalimumab was estimated to be 0.387 (95% confidence interval 0.210-0.570). The incremental cost-effectiveness ratio (ICER) of adalimumab versus no biologic is ?18,500 per quality-adjusted life-year (QALY). The ICER increases to ?19,500 per QALY if the responses are independent.Estimates of ICERs can be sensitive to assumptions about how multiple outcomes are correlated. These assumptions should be explored in univariate and probabilistic sensitivity analyses.",2011-01-08113,21914498,Value Health,David Epstein,0,14 /,793-9,Yes,21914498,"David Epstein; Alex Sutton; Modelling correlated clinical outcomes in health technology appraisal, Value Health, ; 14 ():1098-3015; 793-9",QALY,Not Stated,Not Stated,Not Stated,Adalimumab; patients not responding for arthritis are withdrawn from biologic therapy vs. Placebo,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,18453,United States,2011,21231.71
8536,Modelling correlated clinical outcomes in health technology appraisal,"Many clinical treatments have multiple effects that can only be effectively captured on multiple outcome scales. It might be important to understand how these outcomes are correlated to evaluate the effectiveness and cost-effectiveness of treatments in decision models.The probabilities are estimated that both, one, or neither outcome occurs, given estimates of the marginal probability for each outcome and information about the correlation between them. Methods are shown for different measures of association. Lower and upper bounds for the correlation coefficient are calculated for given values of the marginal probabilities. The approach is illustrated using a simplified decision model based on a recent evaluation of adalimumab, a biologic drug for psoriatic arthritis.Assuming the outcomes are positively correlated, the probability of both a skin and arthritis response after adalimumab was estimated to be 0.387 (95% confidence interval 0.210-0.570). The incremental cost-effectiveness ratio (ICER) of adalimumab versus no biologic is ?18,500 per quality-adjusted life-year (QALY). The ICER increases to ?19,500 per QALY if the responses are independent.Estimates of ICERs can be sensitive to assumptions about how multiple outcomes are correlated. These assumptions should be explored in univariate and probabilistic sensitivity analyses.",2011-01-08113,21914498,Value Health,David Epstein,0,14 /,793-9,Yes,21914498,"David Epstein; Alex Sutton; Modelling correlated clinical outcomes in health technology appraisal, Value Health, ; 14 ():1098-3015; 793-9",QALY,Not Stated,Not Stated,Not Stated,Adalimumab; patients not responding for either skin or arthritis are withdrawn from biologic therapy vs. Placebo,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,20897,United States,2011,24043.73
8537,Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States,"We evaluated the cost-effectiveness of universal mass vaccination (UMV) against influenza compared with a targeted vaccine program (TVP) for selected age and risk groups in the United States.We modeled costs and outcomes of seasonal influenza with UMV and TVP, taking a societal perspective. The US population was stratified to model age-specific (< 5, 5-17, 18-49, 50-64, and 65+ years) vaccine coverage and efficacy. Probability of influenza-related illness (ILI) and complications, health-care utilization, costs, and survival were estimated. For a season's intervention, ILI cases in that year, lifetime costs (2008 US$), and quality-adjusted life years (QALYs) lost (both discounted at 3% per annum) were calculated for each policy and used to derive incremental cost-effectiveness ratios. A range of sensitivity and alternative-scenario analyses were conducted.In base-case analyses, TVP resulted in 63 million ILI cases, 859,000 QALYs lost, and $114.5 billion in direct and indirect costs; corresponding estimates for UMV were 61 million cases, 825,000 QALYs lost, and $111.4 billion. UMV was therefore estimated to dominate TVP, saving $3.1 billion and 34,000 QALYs. In probabilistic sensitivity analyses, UMV was dominant in 82% and dominated in 0% of iterations. In alternative-scenario analyses, UMV dominated TVP when lower estimates of vaccine coverage were used. Lower estimates of ILI risk among unvaccinated, vaccine effectiveness, and risk of complications resulted in ICERs of $2800, $8100, and $15,900 per QALY gained, respectively, for UMV compared with TVP.UMV against seasonal influenza is cost saving in the United States under reasonable assumptions for coverage, cost, and efficacy.",2011-01-08114,21914499,Value Health,Karen M Clements,0,14 /,800-11,Yes,21914499,"Karen M Clements; Jeremy Chancellor; Kristin Nichol; Kelly DeLong; David Thompson; Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States, Value Health, ; 14 ():1098-3015; 800-11",QALY,Not Stated,Not Stated,Not Stated,"Universal mass annual seasonal influenza vaccination for all persons aged 6 months and older vs. Targeted vaccine policy among children aged 6 months to 5 years of age, pregnant women, adults >50 years, persons of any age with certain chronic medical conditions with elevated health risk of influenza complications, nursing home and other long-term care residents, household contacts of and caregivers for high risk individuals",Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-11882.35,United States,2008,-14283.52
8538,Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II),"About 190,000 Germans experience a myocardial infarction each year. Of these, 25% may be eligible for an implantable cardioverter defibrillator (ICD) due to low left ventricular ejection fraction. Given the high costs of implantation, the purpose of this study was to assess the cost-effectiveness of ICDs compared to conventional therapy in patients with an ejection fraction 30% or less after MI in Germany.The economic evaluation was performed from the perspective of the German statutory health insurance. To simulate costs and effectiveness over lifetime, a Markov model was constructed with seven health states. The model was based on 8-year follow-up data for ICD implantation after myocardial infarction (MADIT II), which was published recently.The analysis shows that ICD implantation compared to conventional therapy in patients fulfilling MADIT-II criteria has a cost-effectiveness ratio of ?44,736 per quality-adjusted life year gained. If every patient insured by the statutory health insurance and fulfilling the MADIT-II criteria would receive an ICD, the model suggests expenditures between ?173 million and ?1.7 billion per year.ICD therapy cannot be considered clearly cost-effective when compared to many well-accepted interventions. If policy makers decide to reimburse ICDs in the MADIT-II population, they will need to either raise premiums or abandon coverage for other currently funded medical interventions.",2011-01-08115,21914500,Value Health,Afschin Gandjour,0,14 /,812-7,Yes,21914500,"Afschin Gandjour; Astrid Holler; Dipl-Ges-?k; Charles Christian Adarkwah; Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II), Value Health, ; 14 ():1098-3015; 812-7",QALY,Germany,Not Stated,Not Stated,Implantable cardioverter defibrillators (ICD) vs. Conventional therapy,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,44736,Euro,2009,75207.19
8539,Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control,"Hemodynamic control can improve the outcome of surgery. Esophageal Doppler monitoring measures blood flow by ultrasound waves. This work investigates the cost-effectiveness of this procedure during colorectal resection.Meta-analyses of randomized controlled trials of esophageal Doppler monitoring used in colorectal resection were conducted to help determine its cost-effectiveness. An analytical decision model was used to compare the cost-effectiveness of strategies involving conventional clinical assessment with or without the measurement of central venous pressure, with or without esophageal Doppler monitoring. Avoided mortality and avoided major complications were used as measures of clinical effectiveness.In the meta-analyses comparing conventional clinical assessment plus central venous pressure monitoring with or without esophageal Doppler monitoring, statistically significant differences in total and major complications favoring the use of Doppler were found. No differences were seen in mortality. The use of esophageal Doppler monitoring was associated with lower costs, mainly due to fewer complications, shorter hospital stays and shorter surgery times.Although the information regarding the clinical effectiveness of esophageal Doppler monitoring in colorectal resection is limited, strategies including this form of blood flow monitoring may be cost-effective. Further comparisons of Doppler monitoring against other hemodynamic monitoring systems should be undertaken.",2011-01-08116,21914501,Value Health,Sergio Maeso,0,14 /,818-26,Yes,21914501,"Sergio Maeso; Daniel Callejo; Rodolfo Hern?ndez; Juan A Blasco; Elena Andradas; Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control, Value Health, ; 14 ():1098-3015; 818-26",QALY,Not Stated,Not Stated,Not Stated,Conventional clinical assessment (CCA) + central venous pressure (CVP) + esophageal doppler monitoring (EDM) for hemodynamic control vs. Conventional clinical assessment (CCA) + esophageal doppler monitoring,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,Not Stated,Not Stated,118.65,Euro,2007,203.06
8540,Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control,"Hemodynamic control can improve the outcome of surgery. Esophageal Doppler monitoring measures blood flow by ultrasound waves. This work investigates the cost-effectiveness of this procedure during colorectal resection.Meta-analyses of randomized controlled trials of esophageal Doppler monitoring used in colorectal resection were conducted to help determine its cost-effectiveness. An analytical decision model was used to compare the cost-effectiveness of strategies involving conventional clinical assessment with or without the measurement of central venous pressure, with or without esophageal Doppler monitoring. Avoided mortality and avoided major complications were used as measures of clinical effectiveness.In the meta-analyses comparing conventional clinical assessment plus central venous pressure monitoring with or without esophageal Doppler monitoring, statistically significant differences in total and major complications favoring the use of Doppler were found. No differences were seen in mortality. The use of esophageal Doppler monitoring was associated with lower costs, mainly due to fewer complications, shorter hospital stays and shorter surgery times.Although the information regarding the clinical effectiveness of esophageal Doppler monitoring in colorectal resection is limited, strategies including this form of blood flow monitoring may be cost-effective. Further comparisons of Doppler monitoring against other hemodynamic monitoring systems should be undertaken.",2011-01-08116,21914501,Value Health,Sergio Maeso,0,14 /,818-26,Yes,21914501,"Sergio Maeso; Daniel Callejo; Rodolfo Hern?ndez; Juan A Blasco; Elena Andradas; Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control, Value Health, ; 14 ():1098-3015; 818-26",QALY,Not Stated,Not Stated,Not Stated,Conventional clinical assessment (CCA) + central venous pressure (CVP) + esophageal doppler monitoring (EDM) for hemodynamic control vs. Conventional clinical assessment (CCA) + central venous pressure (CVP),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,Not Stated,Not Stated,-3947.62,Euro,2007,-6755.98
8541,Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control,"Hemodynamic control can improve the outcome of surgery. Esophageal Doppler monitoring measures blood flow by ultrasound waves. This work investigates the cost-effectiveness of this procedure during colorectal resection.Meta-analyses of randomized controlled trials of esophageal Doppler monitoring used in colorectal resection were conducted to help determine its cost-effectiveness. An analytical decision model was used to compare the cost-effectiveness of strategies involving conventional clinical assessment with or without the measurement of central venous pressure, with or without esophageal Doppler monitoring. Avoided mortality and avoided major complications were used as measures of clinical effectiveness.In the meta-analyses comparing conventional clinical assessment plus central venous pressure monitoring with or without esophageal Doppler monitoring, statistically significant differences in total and major complications favoring the use of Doppler were found. No differences were seen in mortality. The use of esophageal Doppler monitoring was associated with lower costs, mainly due to fewer complications, shorter hospital stays and shorter surgery times.Although the information regarding the clinical effectiveness of esophageal Doppler monitoring in colorectal resection is limited, strategies including this form of blood flow monitoring may be cost-effective. Further comparisons of Doppler monitoring against other hemodynamic monitoring systems should be undertaken.",2011-01-08116,21914501,Value Health,Sergio Maeso,0,14 /,818-26,Yes,21914501,"Sergio Maeso; Daniel Callejo; Rodolfo Hern?ndez; Juan A Blasco; Elena Andradas; Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control, Value Health, ; 14 ():1098-3015; 818-26",QALY,Not Stated,Not Stated,Not Stated,Conventional clinical assessment (CCA) + central venous pressure (CVP) + esophageal doppler monitoring (EDM) for hemodynamic control vs. Conventional clinical assessment (CCA),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,Not Stated,Not Stated,-302.92,Euro,2007,-518.42
8542,Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control,"Hemodynamic control can improve the outcome of surgery. Esophageal Doppler monitoring measures blood flow by ultrasound waves. This work investigates the cost-effectiveness of this procedure during colorectal resection.Meta-analyses of randomized controlled trials of esophageal Doppler monitoring used in colorectal resection were conducted to help determine its cost-effectiveness. An analytical decision model was used to compare the cost-effectiveness of strategies involving conventional clinical assessment with or without the measurement of central venous pressure, with or without esophageal Doppler monitoring. Avoided mortality and avoided major complications were used as measures of clinical effectiveness.In the meta-analyses comparing conventional clinical assessment plus central venous pressure monitoring with or without esophageal Doppler monitoring, statistically significant differences in total and major complications favoring the use of Doppler were found. No differences were seen in mortality. The use of esophageal Doppler monitoring was associated with lower costs, mainly due to fewer complications, shorter hospital stays and shorter surgery times.Although the information regarding the clinical effectiveness of esophageal Doppler monitoring in colorectal resection is limited, strategies including this form of blood flow monitoring may be cost-effective. Further comparisons of Doppler monitoring against other hemodynamic monitoring systems should be undertaken.",2011-01-08116,21914501,Value Health,Sergio Maeso,0,14 /,818-26,Yes,21914501,"Sergio Maeso; Daniel Callejo; Rodolfo Hern?ndez; Juan A Blasco; Elena Andradas; Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control, Value Health, ; 14 ():1098-3015; 818-26",QALY,Not Stated,Not Stated,Not Stated,Conventional clinical assessment (CCA) + esophageal doppler monitoring (EDM) for hemodynamic control vs. Conventional clinical assessment (CCA),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,Not Stated,Not Stated,-19133.33,Euro,2007,-32744.89
8543,Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control,"Hemodynamic control can improve the outcome of surgery. Esophageal Doppler monitoring measures blood flow by ultrasound waves. This work investigates the cost-effectiveness of this procedure during colorectal resection.Meta-analyses of randomized controlled trials of esophageal Doppler monitoring used in colorectal resection were conducted to help determine its cost-effectiveness. An analytical decision model was used to compare the cost-effectiveness of strategies involving conventional clinical assessment with or without the measurement of central venous pressure, with or without esophageal Doppler monitoring. Avoided mortality and avoided major complications were used as measures of clinical effectiveness.In the meta-analyses comparing conventional clinical assessment plus central venous pressure monitoring with or without esophageal Doppler monitoring, statistically significant differences in total and major complications favoring the use of Doppler were found. No differences were seen in mortality. The use of esophageal Doppler monitoring was associated with lower costs, mainly due to fewer complications, shorter hospital stays and shorter surgery times.Although the information regarding the clinical effectiveness of esophageal Doppler monitoring in colorectal resection is limited, strategies including this form of blood flow monitoring may be cost-effective. Further comparisons of Doppler monitoring against other hemodynamic monitoring systems should be undertaken.",2011-01-08116,21914501,Value Health,Sergio Maeso,0,14 /,818-26,Yes,21914501,"Sergio Maeso; Daniel Callejo; Rodolfo Hern?ndez; Juan A Blasco; Elena Andradas; Esophageal Doppler monitoring during colorectal resection offers cost-effective improvement of hemodynamic control, Value Health, ; 14 ():1098-3015; 818-26",QALY,Not Stated,Not Stated,Not Stated,Conventional clinical assessment (CCA) + esophageal doppler monitoring (EDM) for hemodynamic control vs. Conventional clinical assessment (CCA) + central venous pressure (CVP),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Not Stated / None,Not Stated,Not Stated,874.34,Euro,2007,1496.34
8544,A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer,"Bevacizumab is approved for treatment of advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy based on a 2-month median survival benefit demonstrated in one randomized trial. The cost-utility of adding bevacizumab to chemotherapy in advanced NSCLC remains unknown. We evaluated the cost-utility of bevacizumab added to chemotherapy in patients with advanced NSCLC.We developed a Markov model to estimate quality-adjusted life years (QALYs) and direct medical costs from the US payer perspective in patients treated with bevacizumab plus chemotherapy and compared these outcomes with patients treated with chemotherapy alone. We populated the model with survival and toxicity data from the clinical trial that compared the two strategies. We obtained utilities from a literature search and unit costs from Medicare. We discounted QALYs and costs at 3% per year. We addressed uncertainty with one-way and probabilistic sensitivity analyzes.Compared with chemotherapy alone, bevacizumab and chemotherapy increased mean QALYs by 0.13, at an incremental life-time cost of US$72,000 per patient. The incremental cost-utility ratio (ICUR) was US$560,000/QALY. The ICUR was most sensitive to the survival on bevacizumab treatment, the drug costs of bevacizumab, and the utility of stable disease on treatment. At a threshold of US$100,000/QALY, the addition of bevacizumab had a 0.2% probability of being cost-effective.Bevacizumab does not appear to be cost-effective when added to chemotherapy in patients with advanced NSCLC, based on approximate cost-effectiveness thresholds that have been identified in the United States. These results may inform decision-makers about resource allocation for NSCLC care.",2011-01-08117,21914503,Value Health,Bernardo Goulart,0,14 /,836-45,Yes,21914503,"Bernardo Goulart; Scott Ramsey; A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer, Value Health, ; 14 ():1098-3015; 836-45",QALY,Not Stated,Not Stated,Not Stated,6 cycles of carboplatin and paclitaxel (200mg/sq.m) plus bevacizumab (15mg/kg) given intravenously for 3 weeks vs. 6 cycles of carboplatin and paclitaxel (200mg/sq.m) given intravenously for 3 weeks,Not Stated,Not Stated,Not Stated,"Female, Male",Full,4 Years,3.00,3.00,559609.48,United States,2010,664201.35
8545,Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis,"Hyperphosphatemia is a common and harmful condition in patients with chronic kidney disease (CKD). We determined the cost-effectiveness of the noncalcium-based phosphate binder lanthanum carbonate (LC) as second-line treatment of hyperphosphatemia after therapy failure with calcium-based binders (CB).Two CKD populations were modeled: 1) predialysis CKD patients and 2) incident dialysis patients. Patients not responding to CB with a serum phosphate (SP) level >5.5 mg/dl received a trial with LC. Patients not responding to LC (SP >4.6 mg/dl) returned to CB treatment. Patient-level data were obtained from clinical trials in predialysis and dialysis. Time-dependent, life-long Markov models (discounting at 3.5% annually) were developed, using a UK National Health Service perspective.The health gains with second-line LC treatment compared to CB treatment were 44 and 56 quality-adjusted life-years (QALYs) for the predialysis and incident dialysis populations, respectively. Second-line LC was a cost-saving strategy in the predialysis population because of the cost-savings of delayed CKD progression. Second-line LC was cost-effective at ?6900 (90% probability interval: ?5800-?8300) per QALY gained in the dialysis population. Results were robust to plausible variations in other model parameters; inclusion of future unrelated dialysis costs had a large influence on cost-effectiveness estimates.Second-line treatment with LC is associated with considerable clinical benefits and good value for money in CKD, irrespective of dialysis status. These results support Kidney Disease Outcomes Quality Initiative guidelines to treat CKD patients with hyperphosphatemia irrespective of dialysis status.",2011-01-08118,21914505,Value Health,Stefan Vegter,0,14 /,852-8,Yes,21914505,"Stefan Vegter; Keith Tolley; Michael S Keith; Maarten J Postma; Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis, Value Health, ; 14 ():1098-3015; 852-8",QALY,Not Stated,Not Stated,Not Stated,Lanthanum carbonate (LC) treatment vs. Calcium-based phosphate binders (CBs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,-7687.07,United Kingdom,2009,-13427.29
8546,Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis,"Hyperphosphatemia is a common and harmful condition in patients with chronic kidney disease (CKD). We determined the cost-effectiveness of the noncalcium-based phosphate binder lanthanum carbonate (LC) as second-line treatment of hyperphosphatemia after therapy failure with calcium-based binders (CB).Two CKD populations were modeled: 1) predialysis CKD patients and 2) incident dialysis patients. Patients not responding to CB with a serum phosphate (SP) level >5.5 mg/dl received a trial with LC. Patients not responding to LC (SP >4.6 mg/dl) returned to CB treatment. Patient-level data were obtained from clinical trials in predialysis and dialysis. Time-dependent, life-long Markov models (discounting at 3.5% annually) were developed, using a UK National Health Service perspective.The health gains with second-line LC treatment compared to CB treatment were 44 and 56 quality-adjusted life-years (QALYs) for the predialysis and incident dialysis populations, respectively. Second-line LC was a cost-saving strategy in the predialysis population because of the cost-savings of delayed CKD progression. Second-line LC was cost-effective at ?6900 (90% probability interval: ?5800-?8300) per QALY gained in the dialysis population. Results were robust to plausible variations in other model parameters; inclusion of future unrelated dialysis costs had a large influence on cost-effectiveness estimates.Second-line treatment with LC is associated with considerable clinical benefits and good value for money in CKD, irrespective of dialysis status. These results support Kidney Disease Outcomes Quality Initiative guidelines to treat CKD patients with hyperphosphatemia irrespective of dialysis status.",2011-01-08118,21914505,Value Health,Stefan Vegter,0,14 /,852-8,Yes,21914505,"Stefan Vegter; Keith Tolley; Michael S Keith; Maarten J Postma; Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis, Value Health, ; 14 ():1098-3015; 852-8",QALY,Not Stated,Not Stated,Not Stated,Lanthanum carbonate (LC) treatment vs. Calcium-based phosphate binders (CBs),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.50,3.50,6900,United Kingdom,2009,12052.48
8547,Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes,"ABSTRACT:Our objective was to determine the cost-effectiveness of Continuous Glucose Monitoring (CGM) technology with intensive insulin therapy compared to self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes in the United States.A Markov cohort analysis was used to model the long-term disease progression of 12 different diabetes disease states, using a cycle length of 1 year with a 33-year time horizon. The analysis uses a societal perspective to model a population with a 20-year history of diabetes with mean age of 40. Costs are expressed in $US 2007, effectiveness in quality-adjusted life years (QALYs). Parameter estimates and their ranges were derived from the literature. Utility estimates were drawn from the EQ-5D catalogue. Probabilities were derived from the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study (UKPDS), and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Costs and QALYs were discounted at 3% per year. Univariate and Multivariate probabilistic sensitivity analyses were conducted using 10,000 Monte Carlo simulations.Compared to SMBG, use of CGM with intensive insulin treatment resulted in an expected improvement in effectiveness of 0.52 QALYs, and an expected increase in cost of $23,552, resulting in an ICER of approximately $45,033/QALY. For a willingness-to-pay (WTP) of $100,000/QALY, CGM with intensive insulin therapy was cost-effective in 70% of the Monte Carlo simulations.CGM with intensive insulin therapy appears to be cost-effective relative to SMBG and other societal health interventions.",2011-01-08123,21917132,Cost Eff Resour Alloc,R Brett McQueen,2011,9 /,13,Yes,21917132,"R Brett McQueen; Samuel L Ellis; Jonathan D Campbell; Kavita V Nair; Patrick W Sullivan; Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes, Cost Eff Resour Alloc, ; 9 ():1478-7547; 13",QALY,Not Stated,Not Stated,Not Stated,Monitoring HbA1c with continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) to dictate intensive insulin therapy regimen vs. Self-monitoring of blood glucose (SMBG) to dictate intensive insulin therapy regimen,Not Stated,Not Stated,Not Stated,"Female, Male",Full,33 Years,3.00,3.00,45033,United States,2007,56211.65
8548,The cost-effectiveness of telestroke in the treatment of acute ischemic stroke,"To conduct a cost-effectiveness analysis of telestroke--a 2-way, audiovisual technology that links stroke specialists to remote emergency department physicians and their stroke patients--compared to usual care (i.e., remote emergency departments without telestroke consultation or stroke experts).A decision-analytic model was developed for both 90-day and lifetime horizons. Model inputs were taken from published literature where available and supplemented with western states' telestroke experiences. Costs were gathered using a societal perspective and converted to 2008 US dollars. Quality-adjusted life-years (QALYs) gained were combined with costs to generate incremental cost-effectiveness ratios (ICERs). In the lifetime horizon model, both costs and QALYs were discounted at 3% annually. Both one-way sensitivity analyses and Monte Carlo simulations were performed.In the base case analysis, compared to usual care, telestroke results in an ICER of $108,363/QALY in the 90-day horizon and $2,449/QALY in the lifetime horizon. For the 90-day and lifetime horizons, 37.5% and 99.7% of 10,000 Monte Carlo simulations yielded ICERs <$50,000/QALY, a ratio commonly considered acceptable in the United States.When a lifetime perspective is taken, telestroke appears cost-effective compared to usual care, since telestroke costs are upfront but benefits of improved stroke care are lifelong. If barriers to use such as low reimbursement rates and high equipment costs are reduced, telestroke has the potential to diminish the striking geographic disparities of acute stroke care in the United States.",2011-01-08126,21917781,Neurology,R E Nelson,2011,77 /,1590-8,No,21917781,"R E Nelson; G M Saltzman; E J Skalabrin; B M Demaerschalk; J J Majersik; The cost-effectiveness of telestroke in the treatment of acute ischemic stroke, Neurology, ; 77 ():1526-632X; 1590-8",QALY,Not Stated,Not Stated,Not Stated,Telestroke system: connecting remote community hospitals to tertiary hospitals staffed with stroke specialists by telestroke network vs. Usual care (no telestroke or consultation from stroke specialists),Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,2449,United States,2008,2943.89
8549,Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children =5 years of age in Taiwan,"A Markov model was used to assess the impact of RV5, a pentavalent (G1, G2, G3, G4, P1A[8]) human bovine (WC3 strain) reassortant rotavirus vaccine, on reducing the healthcare burden and cost associated with rotavirus gastroenteritis (RGE) in Taiwan. Other cost-effectiveness analyses for rotavirus vaccination in industrialized countries have produced varying results depending on the input parameters assumed.Vaccination with RV5 is compared to no vaccination in a hypothetical cohort of Taiwanese children during their first 5 years of life to determine the per dose prices at which vaccination would be cost neutral or provide good value based on established standards from the healthcare (direct medical care costs only) and societal (all RGE-related costs) perspectives. The effects of vaccination on RGE healthcare utilization and days of parental work loss missed are based on results from the Rotavirus Efficacy and Safety Trial.Without vaccination there would be 122,526 symptomatic episodes of RGE. Universal vaccination would reduce RGE-related deaths, hospitalizations, emergency department, and outpatient visits by 91.7%, 92.1%, 83.7%, and 73.4%, respectively. The price per dose at which vaccination would be cost-neutral is US$ 21.80 (688 NTD) and US$ 26.20 (827 NTD) from the healthcare and societal perspectives, respectively. At $25 per dose, the cost per QALY gained is US$ 2261 (71,335 NTD) from the healthcare perspective and cost saving from the societal perspective. KEY LIMITATION: The model only assesses the effect of RV5 on vaccinated children and does not account for herd immunity. However, given that high levels of coverage are anticipated in Taiwan, the effects of herd immunity are likely to be short-term.A pentavalent rotavirus vaccination program is likely to substantially reduce the healthcare burden associated with rotavirus gastroenteritis at a cost per QALY ratio within the range defined as cost-effective.",2011-01-08128,21919673,J Med Econ,Robbin F Itzler,2011,14 /,748-58,Yes,21919673,"Robbin F Itzler; Po Yen Chen; Christina Lac; Antoine C El Khoury; John R Cook; Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children =5 years of age in Taiwan, J Med Econ, ; 14 ():1369-6998; 748-58",QALY,Not Stated,Not Stated,Not Stated,Universal vaccination with pentavalent human-bovine reassortant rotavirus vaccine (RV5) against rotavirus gastroenteritis (RGE) vs. None,Not Stated,4 Years,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,Not Stated,United States,2010,Not Stated
8550,Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children =5 years of age in Taiwan,"A Markov model was used to assess the impact of RV5, a pentavalent (G1, G2, G3, G4, P1A[8]) human bovine (WC3 strain) reassortant rotavirus vaccine, on reducing the healthcare burden and cost associated with rotavirus gastroenteritis (RGE) in Taiwan. Other cost-effectiveness analyses for rotavirus vaccination in industrialized countries have produced varying results depending on the input parameters assumed.Vaccination with RV5 is compared to no vaccination in a hypothetical cohort of Taiwanese children during their first 5 years of life to determine the per dose prices at which vaccination would be cost neutral or provide good value based on established standards from the healthcare (direct medical care costs only) and societal (all RGE-related costs) perspectives. The effects of vaccination on RGE healthcare utilization and days of parental work loss missed are based on results from the Rotavirus Efficacy and Safety Trial.Without vaccination there would be 122,526 symptomatic episodes of RGE. Universal vaccination would reduce RGE-related deaths, hospitalizations, emergency department, and outpatient visits by 91.7%, 92.1%, 83.7%, and 73.4%, respectively. The price per dose at which vaccination would be cost-neutral is US$ 21.80 (688 NTD) and US$ 26.20 (827 NTD) from the healthcare and societal perspectives, respectively. At $25 per dose, the cost per QALY gained is US$ 2261 (71,335 NTD) from the healthcare perspective and cost saving from the societal perspective. KEY LIMITATION: The model only assesses the effect of RV5 on vaccinated children and does not account for herd immunity. However, given that high levels of coverage are anticipated in Taiwan, the effects of herd immunity are likely to be short-term.A pentavalent rotavirus vaccination program is likely to substantially reduce the healthcare burden associated with rotavirus gastroenteritis at a cost per QALY ratio within the range defined as cost-effective.",2011-01-08128,21919673,J Med Econ,Robbin F Itzler,2011,14 /,748-58,Yes,21919673,"Robbin F Itzler; Po Yen Chen; Christina Lac; Antoine C El Khoury; John R Cook; Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children =5 years of age in Taiwan, J Med Econ, ; 14 ():1369-6998; 748-58",QALY,Not Stated,Not Stated,Not Stated,Universal vaccination with pentavalent human-bovine reassortant rotavirus vaccine (RV5) against rotavirus gastroenteritis (RGE) vs. None,Not Stated,4 Years,Not Stated,"Female, Male",Full,5 Years,Not Stated,Not Stated,2261,United States,2010,2683.58
8551,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Two magnetic resonance enterography (MRE) scans per year until age 30 followed by use of computed tomography enterography (CTE) vs. Two computed tomography enterography (CTE) scans per year only,Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,57772,United States,2009,69694.41
8552,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Two magnetic resonance enterography (MRE) scans per year until age 40 followed by use of computed tomography enterography (CTE) vs. Two magnetic resonance enterography (MRE) scans per year until age 30 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,68912,United States,2009,83133.37
8553,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Two magnetic resonance enterography (MRE) scans per year until age 50 followed by use of computed tomography enterography (CTE) vs. Two magnetic resonance enterography (MRE) scans per year until age 40 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,88464,United States,2009,106720.32
8554,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Two magnetic resonance enterography (MRE) scans per year until age 60 followed by use of computed tomography enterography (CTE) vs. Two magnetic resonance enterography (MRE) scans per year until age 50 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,113583.34,United States,2009,137023.53
8555,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Two magnetic resonance enterography (MRE) scans per year only vs. Two magnetic resonance enterography (MRE) scans per year only until age 60 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,267198,United States,2009,322339.65
8556,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan per year until age 30 followed by use of computed tomography enterography (CTE) vs. Computed tomography enterography (CTE) scan per year only,Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,54345,United States,2009,65560.18
8557,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan per year until age 40 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan per year until age 30 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,22617.95,United States,2009,27285.62
8558,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan per year until age 50 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan per year until age 40 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,85151,United States,2009,102723.61
8559,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan per year until age 60 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan per year until age 650 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,124217,United States,2009,149851.66
8560,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan vs. Magnetic resonance enterography (MRE) scan per year until age 60 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,269484,United States,2009,325097.41
8561,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every other year until age 30 followed by use of computed tomography enterography (CTE) vs. Computed tomography enterography (CTE) scan every other year only,Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,52969,United States,2009,63900.21
8562,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan very other year until age 40 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan very other year until age 30 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,64251,United States,2009,77510.48
8563,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every other year until age 50 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every other year until age 40 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,93733.34,United States,2009,113077.08
8564,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every other year until age 60 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every other year until age 50 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,170900,United States,2009,206168.63
8565,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every other year only vs. Magnetic resonance enterography (MRE) scan every other year until age 60 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,147000,United States,2009,177336.39
8566,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 5 years until age 30 followed by use of computed tomography enterography (CTE) vs. Computed tomography enterography (CTE) scan every 5 years only,Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,53234,United States,2009,64219.9
8567,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 5 years until age 40 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every 5 years until age 30 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,65011,United States,2009,78427.32
8568,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 5 years until age 50 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every 5 years until age 40 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,116000,United States,2009,139938.92
8569,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 5 years until age 60 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every 5 years until age 50 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,71400,United States,2009,86134.82
8570,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 5 years only vs. Magnetic resonance enterography (MRE) scan every 5 years until age 60 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,316057,United States,2009,381281.68
8571,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 10 years until age 30 followed by use of computed tomography enterography (CTE) vs. Computed tomography enterography (CTE) scan every 10 years only,Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,71550,United States,2009,86315.77
8572,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 10 years until age 40 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every 10 years until age 30 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,47400,United States,2009,57181.94
8573,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 10 years until age 50 followed by use of computed tomography enterography (CTE) vs. Magnetic resonance enterography (MRE) scan every 10 years until age 40 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,61400,United States,2009,74071.12
8574,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 10 years until age 60 followed by use of computed tomography enterography (CTE) vs. Computed tomography enterography (CTE) scan every 10 years only,Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,139148,United States,2009,167863.97
8575,Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease,"BACKGROUND: The aim was to examine the cost-effectiveness of magnetic resonance enterography (MRE) compared with computed tomography enterography (CTE) for routine imaging of small bowel Crohn's disease (CD) patients to reduce patients' life-time radiation-induced cancer risk. METHODS: We developed a Markov model to compare the lifetime costs, benefits (measured in quality-adjusted life-years [QALYs] of survival and cancers averted) and cost-effectiveness of using MRE rather than CTE for routine disease monitoring in hypothetical cohorts of 100,000 20-year-old patients with CD. We assumed each CT radiation exposure conferred an incremental annual risk of developing cancer using the linear, no-threshold model. RESULTS: In the base case of 16 mSv per CTE, we estimated that radiation from CTE resulted in 1,206 to 20,146 additional cancers depending on the frequency of patient monitoring. Compared to using CTE only, using MRE until age 30 and CTE thereafter resulted in incremental cost-effectiveness ratios (ICERs) between $37,538 and $41,031 per life-year (LY) gained and between $52,969 and $57,772 per quality-adjusted life-year (QALY) gained. Using MRE until age 50 resulted in ICERs between $58,022 and $62,648 per LY gained and between $84,250 and $90,982 per QALY gained. In a threshold analysis, any use of MRE had an ICER of greater than $100,000 per QALY gained when CT radiation doses are less than 6.0 mSv per CTE exam. CONCLUSIONS: MRE is likely cost-effective compared to CTE in patients younger than age 50. Low-dose CTE may be an alternative cost-effective choice in the future. (Inflamm Bowel Dis 2011;).",2011-01-08135,21928375,Inflamm Bowel Dis,Lauren E Cipriano,2011,/,,No,21928375,"Lauren E Cipriano; Barrett G Levesque; Gregory S Zaric; Edward V Loftus; William J Sandborn; Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease, Inflamm Bowel Dis, ; ():1536-4844",QALY,Not Stated,Not Stated,Not Stated,Magnetic resonance enterography (MRE) scan every 10 years only vs. Magnetic resonance enterography (MRE) scan every 10 years until age 60 followed by use of computed tomography enterography (CTE),Not Stated,20 Years,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,379819,United States,2009,458202.25
8576,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (70% coverage) along with cervical screening every 3 years from 20 to 60 years of age vs. Human Papillomavirus (HPV) vaccine (70% coverage) along with cervical screening every 5 years from 30 to 60 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,122950,New Zealand,2009,92867.96
8577,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (70% coverage) along with cervical screening every 3 years from 20 to 60 years of age vs. No vaccine along with cervical screening every 3 years from 20 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,7842,New Zealand,2009,5923.31
8578,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 5 years from 30 to 69 years of age vs. No vaccine along with cervical screening every 3 years from 20 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,10169,New Zealand,2009,7680.96
8579,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (50% coverage) along with cervical screening every 5 years from 30 to 60 years of age vs. No vaccine along with cervical screening every 3 years from 20 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,5831,New Zealand,2009,4404.34
8580,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (50% coverage) along with cervical screening every 3 years from 30 to 60 years of age vs. No vaccine along with cervical screening every 3 years from 20 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,5893,New Zealand,2009,4451.17
8581,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (50% coverage) along with cervical screening every 3 years from 20 to 60 years of age vs. Human Papillomavirus (HPV) vaccine (50% coverage) along with cervical screening every 5 years from 30 to 60 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,218146,New Zealand,2009,164772.46
8582,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 3 years from 30 to 69 years of age vs. Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 5 years from 30 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,1111,New Zealand,2009,839.17
8583,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 5 years from 30 to 60 years of age vs. Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 3 years from 30 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,210,New Zealand,2009,158.62
8584,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 3 years from 20 to 60 years of age vs. Human Papillomavirus (HPV) vaccine (90% coverage) along with cervical screening every 3 years from 30 to 60 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,150000,New Zealand,2009,113299.67
8585,Cost-effectiveness of a cervical screening program with human papillomavirus vaccine,"Recent introduction of a quadrivalent human papillomavirus (HPV) vaccine for girls in New Zealand is expected to decrease the incidence of HPV infection as well as resultant cytological abnormalities and cervical cancer. This may affect the cost-effectiveness of the national cervical screening program by reducing the incidence of lesions detected. This study investigates the cost-effectiveness of the current cervical screening policy with and without the HPV vaccine and compares these results with the cost-effectiveness of a range of other screening strategies.A Markov state-transition model was built based on the natural history of HPV and cervical carcinogenesis. The model followed a hypothetical cohort of girls from 12 years to 85 years of age or death, through screening and treatment pathways. The model compared a ""no vaccine and current screening"" strategy with a selection of screening strategies with different age ranges and frequency intervals.The most cost-effective cervical screening strategy in the presence of the HPV vaccine would be screening women aged 30-60 every 5 years. Moving to this screening strategy from the base case of no vaccine and the current New Zealand strategy of screening women aged 20-69 every 3 years is predicted to have an incremental cost per quality-adjusted life-year gained of NZ$9,841 (?4,428).Reducing screening intensity from 3 to 5 years as well as narrowing the screening age range for the vaccinated cohort once they reach mid-twenties is recommended. The importance of achieving a high vaccine uptake in New Zealand remains high.",2011-01-08148,21936972,Int J Technol Assess Health Care,Elizaveta Sopina,2011,27 /,290-7,No,21936972,"Elizaveta Sopina; Toni Ashton; Cost-effectiveness of a cervical screening program with human papillomavirus vaccine, Int J Technol Assess Health Care, ; 27 ():0266-4623; 290-7",QALY,New Zealand,Not Stated,Not Stated,Human Papillomavirus (HPV) vaccine (30% coverage) along with cervical screening every 5 years from 30 to 60 years of age vs. No vaccine along with cervical screening every 3 years from 20 to 69 years of age,Not Stated,85 Years,12 Years,Female,Full,Lifetime,3.00,3.00,3562,New Zealand,2009,2690.49
8586,"Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?","ABSTRACT: INTRODUCTION: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in routine practice for adult patients with severe sepsis and multiple organ systems failing. METHODS: This CEA used data from a prospective cohort study that compared DrotAA versus no DrotAA (control) for severe sepsis patients with multiple organ systems failing admitted to critical care units in England, Wales, and Northern Ireland. The cohort study used case-mix and mortality data from a national audit, linked with a separate audit of DrotAA infusions. Re-admissions to critical care and corresponding mortality were recorded for four years. Patients receiving DrotAA (n = 1,076) were matched to controls (n = 1,650) with a propensity score (Pscore), and Genetic Matching (GenMatch). The CEA projected long-term survival to report lifetime incremental costs per quality-adjusted life year (QALY) overall, and for subgroups with two or three to five organ systems failing at baseline. RESULTS: The incremental costs per QALY for DrotAA were ?30,000 overall, and ?16,000 for the subgroups with three to five organ systems failing. For patients with two organ systems failing, DrotAA resulted in an average loss of one QALY at an incremental cost of ?15,000. When the subgroup with two organ systems was restricted to patients receiving DrotAA within 24 hours, DrotAA led to a gain of 1.2 QALYs at a cost per QALY of ?11,000. The results were robust to other assumptions including the approach taken to projecting long-term outcomes. CONCLUSIONS: DrotAA is cost-effective in routine practice for severe sepsis patients with three to five organ systems failing. For patients with two organ systems failing, this study could not provide unequivocal evidence on the cost-effectiveness of DrotAA.",2011-01-08152,21943177,Crit Care,M Zia Sadique,2011,15 /,R228,No,21943177,"M Zia Sadique; Richard Grieve; David A Harrison; Brian H Cuthbertson; Kathryn M Rowan; Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?, Crit Care, ; 15 ():1466-609X; R228",QALY,Not Stated,Not Stated,Not Stated,Drotrecogin alfa (DrotAA) vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,30000,United Kingdom,2011,55376.48
8587,"Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?","ABSTRACT: INTRODUCTION: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in routine practice for adult patients with severe sepsis and multiple organ systems failing. METHODS: This CEA used data from a prospective cohort study that compared DrotAA versus no DrotAA (control) for severe sepsis patients with multiple organ systems failing admitted to critical care units in England, Wales, and Northern Ireland. The cohort study used case-mix and mortality data from a national audit, linked with a separate audit of DrotAA infusions. Re-admissions to critical care and corresponding mortality were recorded for four years. Patients receiving DrotAA (n = 1,076) were matched to controls (n = 1,650) with a propensity score (Pscore), and Genetic Matching (GenMatch). The CEA projected long-term survival to report lifetime incremental costs per quality-adjusted life year (QALY) overall, and for subgroups with two or three to five organ systems failing at baseline. RESULTS: The incremental costs per QALY for DrotAA were ?30,000 overall, and ?16,000 for the subgroups with three to five organ systems failing. For patients with two organ systems failing, DrotAA resulted in an average loss of one QALY at an incremental cost of ?15,000. When the subgroup with two organ systems was restricted to patients receiving DrotAA within 24 hours, DrotAA led to a gain of 1.2 QALYs at a cost per QALY of ?11,000. The results were robust to other assumptions including the approach taken to projecting long-term outcomes. CONCLUSIONS: DrotAA is cost-effective in routine practice for severe sepsis patients with three to five organ systems failing. For patients with two organ systems failing, this study could not provide unequivocal evidence on the cost-effectiveness of DrotAA.",2011-01-08152,21943177,Crit Care,M Zia Sadique,2011,15 /,R228,No,21943177,"M Zia Sadique; Richard Grieve; David A Harrison; Brian H Cuthbertson; Kathryn M Rowan; Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?, Crit Care, ; 15 ():1466-609X; R228",QALY,Not Stated,Not Stated,Not Stated,Drotrecogin alfa (DrotAA) vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,-15157.73,United Kingdom,2011,-27979.39
8588,"Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?","ABSTRACT: INTRODUCTION: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS). There is little evidence on whether DrotAA is cost-effective in routine clinical practice. We assessed whether DrotAA is cost-effective in routine practice for adult patients with severe sepsis and multiple organ systems failing. METHODS: This CEA used data from a prospective cohort study that compared DrotAA versus no DrotAA (control) for severe sepsis patients with multiple organ systems failing admitted to critical care units in England, Wales, and Northern Ireland. The cohort study used case-mix and mortality data from a national audit, linked with a separate audit of DrotAA infusions. Re-admissions to critical care and corresponding mortality were recorded for four years. Patients receiving DrotAA (n = 1,076) were matched to controls (n = 1,650) with a propensity score (Pscore), and Genetic Matching (GenMatch). The CEA projected long-term survival to report lifetime incremental costs per quality-adjusted life year (QALY) overall, and for subgroups with two or three to five organ systems failing at baseline. RESULTS: The incremental costs per QALY for DrotAA were ?30,000 overall, and ?16,000 for the subgroups with three to five organ systems failing. For patients with two organ systems failing, DrotAA resulted in an average loss of one QALY at an incremental cost of ?15,000. When the subgroup with two organ systems was restricted to patients receiving DrotAA within 24 hours, DrotAA led to a gain of 1.2 QALYs at a cost per QALY of ?11,000. The results were robust to other assumptions including the approach taken to projecting long-term outcomes. CONCLUSIONS: DrotAA is cost-effective in routine practice for severe sepsis patients with three to five organ systems failing. For patients with two organ systems failing, this study could not provide unequivocal evidence on the cost-effectiveness of DrotAA.",2011-01-08152,21943177,Crit Care,M Zia Sadique,2011,15 /,R228,No,21943177,"M Zia Sadique; Richard Grieve; David A Harrison; Brian H Cuthbertson; Kathryn M Rowan; Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?, Crit Care, ; 15 ():1466-609X; R228",QALY,Not Stated,Not Stated,Not Stated,Drotrecogin alfa (DrotAA) vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,16000,United Kingdom,2011,29534.12
8589,Economic evaluation of second generation pneumococcal conjugate vaccines in Norway,"A seven valent pneumococcal conjugate vaccine (PCV7) was introduced in the Norwegian childhood immunization programme in 2006, and since then the incidence of invasive pneumococcal disease has declined substantially. Recently, two new second generation pneumococcal conjugate vaccines have become available, and an update of the economic evidence is needed. The aim of this study was to estimate incremental costs, health effects and cost-effectiveness of the pneumococcal conjugate vaccines PCV7, PCV13 and PHiD-CV in Norway.We used a Markov model to estimate costs and epidemiological burden of pneumococcal- and NTHi-related diseases (invasive pneumococcal disease (IPD), Community Acquired Pneumonia (CAP) and acute otitis media (AOM)) for a specific birth cohort. Using the most relevant evidence and assumptions for a Norwegian setting, we calculated incremental costs, health effects and cost-effectiveness for different vaccination strategies. In addition we performed sensitivity analyses for key parameters, tested key assumptions in scenario analyses and explored overall model uncertainty using probabilistic sensitivity analysis.The model predicts that both PCV13 and PHiD-CV provide more health gains at a lower cost than PCV7. Differences in health gains between the two second generation vaccines are small for invasive pneumococcal disease but larger for acute otitis media and myringotomy procedures. Consequently, PHiD-CV saves more disease treatment costs and indirect costs than PCV13.This study predicts that, compared to PVC13, PHiD-CV entails lower costs and greater benefits if the latter is measured in terms of quality adjusted life years. PVC13 entails more life years gained than PHiD-CV, but those come at a cost of NOK 3.1 million (~?0.4 million) per life year. The results indicate that PHiD-CV is cost-effective compared to PCV13 in the Norwegian setting.",2011-01-08157,21945264,Vaccine,Bjarne Robberstad,2011,29 /,8564-74,Yes,21945264,"Bjarne Robberstad; Carl R Frostad; Per E Akselsen; Kari J Kv?rner; Aud K H Berstad; Economic evaluation of second generation pneumococcal conjugate vaccines in Norway, Vaccine, ; 29 ():1873-2518; 8564-74",QALY,Not Stated,Not Stated,Not Stated,Pneumococcal conjugate vaccine (PCV) 7 vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,4.00,-78.81,Norway,2009,-15.2
8590,Economic evaluation of second generation pneumococcal conjugate vaccines in Norway,"A seven valent pneumococcal conjugate vaccine (PCV7) was introduced in the Norwegian childhood immunization programme in 2006, and since then the incidence of invasive pneumococcal disease has declined substantially. Recently, two new second generation pneumococcal conjugate vaccines have become available, and an update of the economic evidence is needed. The aim of this study was to estimate incremental costs, health effects and cost-effectiveness of the pneumococcal conjugate vaccines PCV7, PCV13 and PHiD-CV in Norway.We used a Markov model to estimate costs and epidemiological burden of pneumococcal- and NTHi-related diseases (invasive pneumococcal disease (IPD), Community Acquired Pneumonia (CAP) and acute otitis media (AOM)) for a specific birth cohort. Using the most relevant evidence and assumptions for a Norwegian setting, we calculated incremental costs, health effects and cost-effectiveness for different vaccination strategies. In addition we performed sensitivity analyses for key parameters, tested key assumptions in scenario analyses and explored overall model uncertainty using probabilistic sensitivity analysis.The model predicts that both PCV13 and PHiD-CV provide more health gains at a lower cost than PCV7. Differences in health gains between the two second generation vaccines are small for invasive pneumococcal disease but larger for acute otitis media and myringotomy procedures. Consequently, PHiD-CV saves more disease treatment costs and indirect costs than PCV13.This study predicts that, compared to PVC13, PHiD-CV entails lower costs and greater benefits if the latter is measured in terms of quality adjusted life years. PVC13 entails more life years gained than PHiD-CV, but those come at a cost of NOK 3.1 million (~?0.4 million) per life year. The results indicate that PHiD-CV is cost-effective compared to PCV13 in the Norwegian setting.",2011-01-08157,21945264,Vaccine,Bjarne Robberstad,2011,29 /,8564-74,Yes,21945264,"Bjarne Robberstad; Carl R Frostad; Per E Akselsen; Kari J Kv?rner; Aud K H Berstad; Economic evaluation of second generation pneumococcal conjugate vaccines in Norway, Vaccine, ; 29 ():1873-2518; 8564-74",QALY,Not Stated,Not Stated,Not Stated,Pneumococcal conjugate vaccine (PCV) 13 vs. Pneumococcal conjugate vaccine (PCV) 7,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,4.00,-429.24,Norway,2009,-82.77
8591,Economic evaluation of second generation pneumococcal conjugate vaccines in Norway,"A seven valent pneumococcal conjugate vaccine (PCV7) was introduced in the Norwegian childhood immunization programme in 2006, and since then the incidence of invasive pneumococcal disease has declined substantially. Recently, two new second generation pneumococcal conjugate vaccines have become available, and an update of the economic evidence is needed. The aim of this study was to estimate incremental costs, health effects and cost-effectiveness of the pneumococcal conjugate vaccines PCV7, PCV13 and PHiD-CV in Norway.We used a Markov model to estimate costs and epidemiological burden of pneumococcal- and NTHi-related diseases (invasive pneumococcal disease (IPD), Community Acquired Pneumonia (CAP) and acute otitis media (AOM)) for a specific birth cohort. Using the most relevant evidence and assumptions for a Norwegian setting, we calculated incremental costs, health effects and cost-effectiveness for different vaccination strategies. In addition we performed sensitivity analyses for key parameters, tested key assumptions in scenario analyses and explored overall model uncertainty using probabilistic sensitivity analysis.The model predicts that both PCV13 and PHiD-CV provide more health gains at a lower cost than PCV7. Differences in health gains between the two second generation vaccines are small for invasive pneumococcal disease but larger for acute otitis media and myringotomy procedures. Consequently, PHiD-CV saves more disease treatment costs and indirect costs than PCV13.This study predicts that, compared to PVC13, PHiD-CV entails lower costs and greater benefits if the latter is measured in terms of quality adjusted life years. PVC13 entails more life years gained than PHiD-CV, but those come at a cost of NOK 3.1 million (~?0.4 million) per life year. The results indicate that PHiD-CV is cost-effective compared to PCV13 in the Norwegian setting.",2011-01-08157,21945264,Vaccine,Bjarne Robberstad,2011,29 /,8564-74,Yes,21945264,"Bjarne Robberstad; Carl R Frostad; Per E Akselsen; Kari J Kv?rner; Aud K H Berstad; Economic evaluation of second generation pneumococcal conjugate vaccines in Norway, Vaccine, ; 29 ():1873-2518; 8564-74",QALY,Not Stated,Not Stated,Not Stated,Pneumococcal conjugate vaccine (Phid-CV) vs. Pneumococcal conjugate vaccine (PCV) 13,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,4.00,4.00,-484.78,Norway,2009,-93.48
8592,Selection for early surgery in asymptomatic mitral regurgitation: a Markov model,"BACKGROUND: Current guidelines propose mitral valve repair in asymptomatic chronic mitral regurgitation (MR) when the likelihood of repair is 90% or more. As this figure is not evidence-based, we sought whether the results of a decision-analytic model could facilitate the selection between early surgery (ES) and watchful waiting (WW) based on current guidelines. METHODS: A Markov model was developed to reflect the anticipated health states in MR (pre-operative, post-operative, post-complication and death). Risks and transitions were informed by the literature. Implications of the strategies for survival, quality-adjusted life years (QALYs), cost and cost-effectiveness were calculated from a US healthcare provider perspective. RESULTS: In the reference case (90% repair), QALY with ES was superior to WW (11.2 [0.4-21.3] vs 10.7 [95%CI: 1.0-21.3]) at an incremental cost-effectiveness of $54,659 ($45,030-$64,288) per QALY. Sensitivity analyses of health benefit showed the main variables influencing outcome were repair rate, operative mortality and risks of heart failure and death with medical management. At the registry repair rate (50%), outcomes of ES were worse than WW, and threshold analysis showed that a repair rate of 84% was required for ES to be superior. High medical risk (yearly heart failure risk 5.6 +/- 6.6% and mortality 2.5 +/- 4%) was the most favorable scenario for surgery; ES was more effective when mortality in the WW group was >3.5%/year. CONCLUSION: A Markov model might be used to guide the selection of asymptomatic patients for mitral repair, based on local variations in risk and complications as well as repair rate.",2011-01-08158,21945713,Int J Cardiol,Thomas H Marwick,2013,165 / 2,,No,21945713,"Thomas H Marwick; Paul A Scuffham; M G Myriam Hunink; Selection for early surgery in asymptomatic mitral regurgitation: a Markov model, Int J Cardiol, 2013 May 10; 165(2):0167-5273",QALY,Not Stated,Not Stated,Not Stated,Early surgery for mitral valve repair vs. Watchful waiting,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,54659,United States,2006,70170.39
8593,Selection for early surgery in asymptomatic mitral regurgitation: a Markov model,"BACKGROUND: Current guidelines propose mitral valve repair in asymptomatic chronic mitral regurgitation (MR) when the likelihood of repair is 90% or more. As this figure is not evidence-based, we sought whether the results of a decision-analytic model could facilitate the selection between early surgery (ES) and watchful waiting (WW) based on current guidelines. METHODS: A Markov model was developed to reflect the anticipated health states in MR (pre-operative, post-operative, post-complication and death). Risks and transitions were informed by the literature. Implications of the strategies for survival, quality-adjusted life years (QALYs), cost and cost-effectiveness were calculated from a US healthcare provider perspective. RESULTS: In the reference case (90% repair), QALY with ES was superior to WW (11.2 [0.4-21.3] vs 10.7 [95%CI: 1.0-21.3]) at an incremental cost-effectiveness of $54,659 ($45,030-$64,288) per QALY. Sensitivity analyses of health benefit showed the main variables influencing outcome were repair rate, operative mortality and risks of heart failure and death with medical management. At the registry repair rate (50%), outcomes of ES were worse than WW, and threshold analysis showed that a repair rate of 84% was required for ES to be superior. High medical risk (yearly heart failure risk 5.6 +/- 6.6% and mortality 2.5 +/- 4%) was the most favorable scenario for surgery; ES was more effective when mortality in the WW group was >3.5%/year. CONCLUSION: A Markov model might be used to guide the selection of asymptomatic patients for mitral repair, based on local variations in risk and complications as well as repair rate.",2011-01-08158,21945713,Int J Cardiol,Thomas H Marwick,2013,165 / 2,,No,21945713,"Thomas H Marwick; Paul A Scuffham; M G Myriam Hunink; Selection for early surgery in asymptomatic mitral regurgitation: a Markov model, Int J Cardiol, 2013 May 10; 165(2):0167-5273",QALY,Not Stated,Not Stated,Not Stated,Early surgery for mitral valve repair vs. Watchful waiting,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,16337,United States,2006,20973.19
8594,Selection for early surgery in asymptomatic mitral regurgitation: a Markov model,"BACKGROUND: Current guidelines propose mitral valve repair in asymptomatic chronic mitral regurgitation (MR) when the likelihood of repair is 90% or more. As this figure is not evidence-based, we sought whether the results of a decision-analytic model could facilitate the selection between early surgery (ES) and watchful waiting (WW) based on current guidelines. METHODS: A Markov model was developed to reflect the anticipated health states in MR (pre-operative, post-operative, post-complication and death). Risks and transitions were informed by the literature. Implications of the strategies for survival, quality-adjusted life years (QALYs), cost and cost-effectiveness were calculated from a US healthcare provider perspective. RESULTS: In the reference case (90% repair), QALY with ES was superior to WW (11.2 [0.4-21.3] vs 10.7 [95%CI: 1.0-21.3]) at an incremental cost-effectiveness of $54,659 ($45,030-$64,288) per QALY. Sensitivity analyses of health benefit showed the main variables influencing outcome were repair rate, operative mortality and risks of heart failure and death with medical management. At the registry repair rate (50%), outcomes of ES were worse than WW, and threshold analysis showed that a repair rate of 84% was required for ES to be superior. High medical risk (yearly heart failure risk 5.6 +/- 6.6% and mortality 2.5 +/- 4%) was the most favorable scenario for surgery; ES was more effective when mortality in the WW group was >3.5%/year. CONCLUSION: A Markov model might be used to guide the selection of asymptomatic patients for mitral repair, based on local variations in risk and complications as well as repair rate.",2011-01-08158,21945713,Int J Cardiol,Thomas H Marwick,2013,165 / 2,,No,21945713,"Thomas H Marwick; Paul A Scuffham; M G Myriam Hunink; Selection for early surgery in asymptomatic mitral regurgitation: a Markov model, Int J Cardiol, 2013 May 10; 165(2):0167-5273",QALY,Not Stated,Not Stated,Not Stated,Early surgery for mitral valve repair vs. Watchful waiting,Not Stated,Not Stated,71 Years,"Female, Male",Full,Lifetime,3.00,3.00,75279,United States,2006,96642.03
8595,Selection for early surgery in asymptomatic mitral regurgitation: a Markov model,"BACKGROUND: Current guidelines propose mitral valve repair in asymptomatic chronic mitral regurgitation (MR) when the likelihood of repair is 90% or more. As this figure is not evidence-based, we sought whether the results of a decision-analytic model could facilitate the selection between early surgery (ES) and watchful waiting (WW) based on current guidelines. METHODS: A Markov model was developed to reflect the anticipated health states in MR (pre-operative, post-operative, post-complication and death). Risks and transitions were informed by the literature. Implications of the strategies for survival, quality-adjusted life years (QALYs), cost and cost-effectiveness were calculated from a US healthcare provider perspective. RESULTS: In the reference case (90% repair), QALY with ES was superior to WW (11.2 [0.4-21.3] vs 10.7 [95%CI: 1.0-21.3]) at an incremental cost-effectiveness of $54,659 ($45,030-$64,288) per QALY. Sensitivity analyses of health benefit showed the main variables influencing outcome were repair rate, operative mortality and risks of heart failure and death with medical management. At the registry repair rate (50%), outcomes of ES were worse than WW, and threshold analysis showed that a repair rate of 84% was required for ES to be superior. High medical risk (yearly heart failure risk 5.6 +/- 6.6% and mortality 2.5 +/- 4%) was the most favorable scenario for surgery; ES was more effective when mortality in the WW group was >3.5%/year. CONCLUSION: A Markov model might be used to guide the selection of asymptomatic patients for mitral repair, based on local variations in risk and complications as well as repair rate.",2011-01-08158,21945713,Int J Cardiol,Thomas H Marwick,2013,165 / 2,,No,21945713,"Thomas H Marwick; Paul A Scuffham; M G Myriam Hunink; Selection for early surgery in asymptomatic mitral regurgitation: a Markov model, Int J Cardiol, 2013 May 10; 165(2):0167-5273",QALY,Not Stated,Not Stated,Not Stated,Early surgery for mitral valve repair (50% repair rate) vs. Watchful waiting,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-129539.13,United States,2006,-166300.35
8596,The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands,"The use of human papillomavirus (HPV) vaccines has been universally approved for women from age 12 to 25 years, but those older than 16 years receive no reimbursement for the cost of the vaccine in the Netherlands. Reductions in the vaccine price as well as new insights in the efficacy of HPV vaccines offer renewed arguments to consider HPV vaccination in adult women. We calculated the clinical benefit and cost-effectiveness of vaccinating women aged 17-25 years in 2010.The calculations were based on an individual-based simulation model for cervical carcinogenesis, with HPV infection risks obtained from a type-specific HPV transmission model. The indirect protective effect from vaccinating 12 to 16 year-old girls was adjusted for. Cervical screening in the model was incorporated according Dutch screening guidelines, i.e. 7 cytology-based rounds at 5-year intervals from the age of 30. As base-case, we assumed the vaccine to offer full protection against HPV16/18 only if no prior exposure to that type had occurred before vaccination. In sensitivity analyses, we considered partial cross-protection against types 31/33/45/58 and efficacy against all future infections, irrespective of previous or current infection status.In base-case analyses, vaccinating 17 year-olds reduced their lifetime risk of treatment for precancerous lesions from 7.77% to 3.48% and their lifetime cervical cancer risk from 0.52% to 0.24%. These risks were 6.12% and 0.45%, respectively, for a 25 year-old vaccinee. The incremental cost-effectiveness ratio (ICER) for vaccinating 17-25 year-olds was ?22,526 per quality-adjusted life-year (QALY) at a vaccine price of ?65 per dose, a 50% reduction of the 2010 pharmacy price in the Netherlands. If cross-protection against types 31/33/45/58 was included, the ICER decreased to ?14,734 per QALY. Results were robust to efficacy assumptions with respect to previous or current infection status.The clinical benefit of HPV vaccination of women up to 25 years moderately depends on cross-protection to non-vaccine types. Refunding the cost of the vaccine to 17-25 year-old women in the Netherlands can be considered cost-effective at anticipated price reductions.",2011-01-08160,21945961,Vaccine,Johannes A Bogaards,2011,29 /,8929-36,Yes,21945961,"Johannes A Bogaards; Veerle M H Coup?; Chris J L M Meijer; Johannes Berkhof; The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands, Vaccine, ; 29 ():1873-2518; 8929-36",QALY,Netherlands,Not Stated,Not Stated,Human papillomavirus (HPV) vaccination vs. None,Not Stated,25 Years,17 Years,Female,Full,Lifetime,4.00,1.50,22526,Euro,2010,35383.6
8597,Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk,"Although statins have been shown to reduce the risk of cardiovascular events in patients at low cardiovascular risk, their absolute benefit is small in the short term, which may adversely affect cost-effectiveness. We sought to determine the long-term cost-effectiveness (beyond the duration of clinical trials) of low- and high-potency statins in patients at low cardiovascular risk and to estimate the impact on Canada's publicly funded health care system.Using Markov modelling, we performed a cost-utility analysis in which we compared low-potency statins (fluvastatin, lovastatin, pravastatin and simvastatin) and high-potency statins (atorvastatin and rosuvastatin) with no statins in a simulated cohort of low-risk patients over a lifetime horizon. Model outcomes included costs (in 2010 Canadian dollars), quality-adjusted life-years (QALYs) gained and the cost per QALY gained.Over a lifetime horizon, the cost of managing a patient at low cardiovascular risk was estimated to be about $10,100 without statins, $15,200 with low-potency statins and $16,400 with high-potency statins. The cost per QALY gained with high-potency statins (v. no statins) was $21 300; the use of low-potency statins was not considered economically attractive. These results were robust to sensitivity analyses, although their use became economically unattractive when the duration of benefit from statin use was assumed to be less than 10 years.Use of high-potency statins in patients at low cardiovascular risk was associated with a cost per QALY gained that was economically attractive by current standards, assuming that the benefit from statin use would continue for at least 10 years. However, the overall expenditure on statins would be substantial, and the ramifications of this practice should be carefully considered by policy-makers.",2011-01-08167,21989469,CMAJ,Jon Conly,2011,183 /,E1180-8,No,21989469,"Jon Conly; Fiona Clement; Marcello Tonelli; Brenda Hemmelgarn; Scott Klarenbach; Anita Lloyd; Finlay A McAlister; Don Husereau; Natasha Wiebe; Flora Au; Braden Manns; Alberta Kidney Disease Network; Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk, CMAJ, ; 183 ():1488-2329; E1180-8",QALY,Canada,Not Stated,Not Stated,Low-potency statins vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,30000,Canada,2010,34588.62
8598,Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk,"Although statins have been shown to reduce the risk of cardiovascular events in patients at low cardiovascular risk, their absolute benefit is small in the short term, which may adversely affect cost-effectiveness. We sought to determine the long-term cost-effectiveness (beyond the duration of clinical trials) of low- and high-potency statins in patients at low cardiovascular risk and to estimate the impact on Canada's publicly funded health care system.Using Markov modelling, we performed a cost-utility analysis in which we compared low-potency statins (fluvastatin, lovastatin, pravastatin and simvastatin) and high-potency statins (atorvastatin and rosuvastatin) with no statins in a simulated cohort of low-risk patients over a lifetime horizon. Model outcomes included costs (in 2010 Canadian dollars), quality-adjusted life-years (QALYs) gained and the cost per QALY gained.Over a lifetime horizon, the cost of managing a patient at low cardiovascular risk was estimated to be about $10,100 without statins, $15,200 with low-potency statins and $16,400 with high-potency statins. The cost per QALY gained with high-potency statins (v. no statins) was $21 300; the use of low-potency statins was not considered economically attractive. These results were robust to sensitivity analyses, although their use became economically unattractive when the duration of benefit from statin use was assumed to be less than 10 years.Use of high-potency statins in patients at low cardiovascular risk was associated with a cost per QALY gained that was economically attractive by current standards, assuming that the benefit from statin use would continue for at least 10 years. However, the overall expenditure on statins would be substantial, and the ramifications of this practice should be carefully considered by policy-makers.",2011-01-08167,21989469,CMAJ,Jon Conly,2011,183 /,E1180-8,No,21989469,"Jon Conly; Fiona Clement; Marcello Tonelli; Brenda Hemmelgarn; Scott Klarenbach; Anita Lloyd; Finlay A McAlister; Don Husereau; Natasha Wiebe; Flora Au; Braden Manns; Alberta Kidney Disease Network; Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk, CMAJ, ; 183 ():1488-2329; E1180-8",QALY,Canada,Not Stated,Not Stated,High-potency statin vs. None,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,21300,Canada,2010,24557.92
8599,Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk,"Although statins have been shown to reduce the risk of cardiovascular events in patients at low cardiovascular risk, their absolute benefit is small in the short term, which may adversely affect cost-effectiveness. We sought to determine the long-term cost-effectiveness (beyond the duration of clinical trials) of low- and high-potency statins in patients at low cardiovascular risk and to estimate the impact on Canada's publicly funded health care system.Using Markov modelling, we performed a cost-utility analysis in which we compared low-potency statins (fluvastatin, lovastatin, pravastatin and simvastatin) and high-potency statins (atorvastatin and rosuvastatin) with no statins in a simulated cohort of low-risk patients over a lifetime horizon. Model outcomes included costs (in 2010 Canadian dollars), quality-adjusted life-years (QALYs) gained and the cost per QALY gained.Over a lifetime horizon, the cost of managing a patient at low cardiovascular risk was estimated to be about $10,100 without statins, $15,200 with low-potency statins and $16,400 with high-potency statins. The cost per QALY gained with high-potency statins (v. no statins) was $21 300; the use of low-potency statins was not considered economically attractive. These results were robust to sensitivity analyses, although their use became economically unattractive when the duration of benefit from statin use was assumed to be less than 10 years.Use of high-potency statins in patients at low cardiovascular risk was associated with a cost per QALY gained that was economically attractive by current standards, assuming that the benefit from statin use would continue for at least 10 years. However, the overall expenditure on statins would be substantial, and the ramifications of this practice should be carefully considered by policy-makers.",2011-01-08167,21989469,CMAJ,Jon Conly,2011,183 /,E1180-8,No,21989469,"Jon Conly; Fiona Clement; Marcello Tonelli; Brenda Hemmelgarn; Scott Klarenbach; Anita Lloyd; Finlay A McAlister; Don Husereau; Natasha Wiebe; Flora Au; Braden Manns; Alberta Kidney Disease Network; Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk, CMAJ, ; 183 ():1488-2329; E1180-8",QALY,Canada,Not Stated,Not Stated,High-potency statin vs. Low-potency statin,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,5.00,5.00,9230.77,Canada,2010,10642.65
8600,Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD,"To conduct a cost-effectiveness analysis comparing roflumilast/tiotropium therapy vs tiotropium monotherapy in patients with severe-to-very severe COPD.The economic evaluation applied a disease-based Markov cohort model with five health states: (1) severe COPD, (2) severe COPD with a history of severe exacerbation, (3) very severe COPD, (4) very severe COPD with a history of severe exacerbation, and (5) death. Within a given health state, a patient may have a mild/moderate or severe exacerbation or die. Data from roflumilast clinical trials and published literature were used to populate model parameters. The model calculated health outcomes and costs for roflumilast/tiotropium therapy vs tiotropium monotherapy over a 5-year horizon. Incremental cost and benefits were then calculated as cost-effectiveness ratios, including cost per exacerbation avoided and cost per quality adjusted life year ($/QALY).Over a 5-year horizon, the estimated incremental costs per exacerbation and per severe exacerbation avoided were $589 and $5869, respectively, and the incremental cost per QALY was $15,815. One-way sensitivity analyses varying key parameters produced an incremental cost per QALY ranging from $1963-$32,773.A number of key parameters used in the model were obtained from studies in the literature that were conducted under different contexts. Specifically, the relative risk estimate for severe COPD patients originates from a small trial not designed to demonstrate the impact of roflumilast on frequency of exacerbations. In addition, the model extrapolates the relative risk estimates over periods of 5-30 years, even though the estimates were only observed in trials that spanned less than a year.The addition of roflumilast to tiotropium is cost-effective for the treatment of severe to very severe COPD patients.",2011-01-08169,21992217,J Med Econ,Shawn X Sun,2011,14 /,805-15,Yes,21992217,"Shawn X Sun; Maryna Marynchenko; Ritesh Banerjee; David Cheng; Michelle Mocarski; Donald Yin; Andrew P Yu; Eric Q Wu; Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD, J Med Econ, ; 14 ():1369-6998; 805-15",QALY,Not Stated,Not Stated,Not Stated,Roflumilast/tiotropium therapy vs. Tiotropium monotherapy,Not Stated,Not Stated,Not Stated,"Female, Male",Full,5 Years,3.00,3.00,15815,United States,2009,19078.74
